Document:

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (this “Agreement”) is made and entered into as of April 4, 2016, by and between MRI Interventions,
Inc., a Delaware corporation (the “Company”), and Brainlab AG, a German corporation (the “Purchaser”).

 

RECITALS

 

This Agreement is made
pursuant to the Securities Purchase Agreement dated March 22, 2016 between the Company and the Purchaser (the “Purchase
Agreement”).

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

1.          
Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall
have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following
meanings:

 

“Advice”
has the meaning set forth in Section 6(c).

 

“Allowable
Suspension Period” has the meaning set forth in Section 6(c).

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

“Commission”
means the Securities and Exchange Commission.

 

“Common Stock”
means the common stock of the Company, par value $0.01 per share, and any securities into which such common stock may hereinafter
be reclassified.

 

“Company”
has the meaning set forth in the Preamble.

 

“Effective
Date” means the date that the Registration Statement filed pursuant to Section 2(a) is first declared effective
by the Commission.

 

“Effectiveness
Deadline” means, with respect to the Initial Registration Statement or the New Registration Statement, the seventy-fifth
(75th) calendar day following the Closing Date (or, in the event the Commission reviews and has written comments to
the Initial Registration Statement or the New Registration Statement, the one hundred twentieth (120th) calendar day following
the Closing Date); provided, however, that if the Company is notified by the Commission that the Initial Registration Statement
or the New Registration Statement will not be reviewed or is no longer subject to further review and comments, the Effectiveness
Deadline as to such Registration Statement shall be the fifth (5th) Trading Day following the date on which the Company is
so notified if such date precedes the dates otherwise required above; provided, further, that if the Effectiveness Deadline falls
on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline shall be extended to
the next Business Day on which the Commission is open for business.

 

“Effectiveness
Period” has the meaning set forth in Section 2(b).

 

“Event”
has the meaning set forth in Section 2(c).

 

“Event Date”
has the meaning set forth in Section 2(c).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

    	1

    	 

    

 

“Filing Deadline”
means, with respect to the Initial Registration Statement required to be filed pursuant to Section 2(a), the thirtieth
(30th) calendar day following the Closing Date; provided, however, that if the Filing Deadline falls on a Saturday,
Sunday or other day that the Commission is closed for business, the Filing Deadline shall be extended to the next Business Day
on which the Commission is open for business.

 

“FINRA”
has meaning set forth in Section 3(i).

 

“Indemnified
Party” has the meaning set forth in Section 5(c).

 

“Indemnifying
Party” has the meaning set forth in Section 5(c).

 

“Initial Registration
Statement” has the meaning set forth in Section 2(a).

 

“Losses”
has the meaning set forth in Section 5(a).

 

“New Registration
Statement” has the meaning set forth in Section 2(a).

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective Registration Statement in reliance upon Rule 430A promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of
any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to such
prospectus, including post effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such prospectus.

 

“Purchase
Agreement” has the meaning set forth in the Recitals.

 

“Purchaser”
has the meaning set forth in the Preamble.

 

“Registrable
Securities” means all of (i) the Shares, (ii) the Warrant Shares and (iii) any securities issued or issuable
upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; provided,
that the Purchaser has completed and delivered to the Company a Selling Stockholder Questionnaire; and, provided further, that
Purchaser’s Shares and Warrant Shares shall cease to be Registrable Securities upon the earliest to occur of the following:
(A) a sale pursuant to a Registration Statement or Rule 144 under the Securities Act (in which case, only such Shares or Warrant
Shares sold by the Purchaser shall cease to be a Registrable Securities and the remaining Shares or Warrant Shares held by Purchaser
shall continue to be Registrable Securities); or (B) becoming eligible for resale by the Purchaser under Rule 144 without
the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume
or manner-of-sale restrictions (assuming for purposes of the foregoing determination, “cashless exercise” of all Warrants)
as determined by Company Counsel, pursuant to a written opinion letter to such effect that is addressed and delivered to, and reasonably
acceptable to, the Transfer Agent. For the sake of clarity, Registrable Securities shall include any Warrant Shares transferred
by Purchaser pursuant to the Evercore Transfer (as defined in the Purchase Agreement).

 

“Registration
Delay Payments” has the meaning set forth in Section 2(c).

 

“Registration
Statements” means any one or more registration statements of the Company filed under the Securities Act that covers the
resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including, without limitation, the Initial
Registration Statement, the New Registration Statement and any Remainder Registration Statement), amendments and supplements to
such registration statements, including post-effective amendments, and all exhibits and all material incorporated by reference
or deemed to be incorporated by reference in such registration statements.

 

“Remainder
Registration Statement” has the meaning set forth in Section 2(a).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

    	2

    	 

    

 

“Rule 415”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Rule 424”
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“SEC Guidance”
means (i) any publicly-available written guidance, comments, requirements or requests of the Commission staff and (ii) the
Securities Act.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Selling Stockholder
Questionnaire” means a questionnaire in the form attached as Annex B hereto, or such other form of questionnaire
as may reasonably be adopted by the Company from time to time.

 

“Shares”
means the shares of Common Stock issued or issuable to the Purchaser pursuant to the Purchase Agreement, other than the Warrant
Shares.

 

“Warrants”
means the A Warrants (as defined in the Purchase Agreement) and B Warrants (as defined in the Purchase Agreement) issued pursuant
to the Purchase Agreement. “Warrant Shares” means the shares of Common Stock issued or issuable upon exercise
of the Warrants.

 

		2.	Registration.

 

(a)          
On or prior to the Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement covering
the resale of all of the Registrable Securities not already covered by an existing and effective Registration Statement for an
offering to be made on a continuous basis pursuant to Rule 415 or, if Rule 415 is not available for offers and sales of the Registrable
Securities, by such other means of distribution of Registrable Securities as the Company may reasonably determine (the “Initial
Registration Statement”). The Initial Registration Statement shall be on Form S-1 or such other form available to the
Company to register for resale the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e),
and shall contain (except if otherwise required pursuant to written comments received from the Commission upon a review of such
Registration Statement) the “Plan of Distribution” section substantially in the form attached hereto as Annex A
(which may be modified to respond to comments, if any, provided by the Commission). Notwithstanding the registration obligations
set forth in this Section 2, in the event the Commission informs the Company that all of the Registrable Securities
cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement,
the Company agrees to promptly (i) inform Purchaser thereof and use its commercially reasonable efforts to file amendments
to the Initial Registration Statement as required by the Commission and/or (ii) withdraw the Initial Registration Statement
and file a new registration statement (a “New Registration Statement”), in either case covering the maximum
number of Registrable Securities permitted to be registered by the Commission, on such form available to the Company to register
for resale the Registrable Securities as a secondary offering; provided, however, that prior to filing such amendment or New Registration
Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Securities Act Rules Compliance
and Disclosure Interpretation 612.09. Notwithstanding any other provision of this Agreement, if any SEC Guidance sets forth a limitation
of the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering
(and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater
number of Registrable Securities), the number of Registrable Securities to be registered on such Registration Statement will be
reduced to comply therewith. In the event the Company amends the Initial Registration Statement or files a New Registration Statement,
as the case may be, under clauses (i) or (ii) above, the Company will use its commercially reasonable efforts to file
with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities
in general, one or more registration statements on such form available to the Company to register for resale those Registrable
Securities that

 

    	3

    	 

    

 

were
not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement (each, a “Remainder
Registration Statement”).

 

(b)          
The Company shall use its best efforts to cause each Registration Statement to be declared effective by the Commission as
soon as practicable and, with respect to the Initial Registration Statement or a New Registration Statement, as applicable, no
later than the Effectiveness Deadline (including filing with the Commission a request for acceleration of effectiveness in accordance
with Rule 461 promulgated under the Securities Act), and shall use its commercially reasonable efforts to keep each Registration
Statement continuously effective under the Securities Act until earlier of (i) such time as all of the Registrable Securities covered
by such Registration Statement have been publicly sold by the Purchaser or (ii) the date that all Registrable Securities covered
by such Registration Statement may be sold by non-affiliates without volume or manner-of-sale restrictions under Rule 144, without
the requirement for the Company to be in compliance with the current public information requirements under Rule 144 (assuming for
purposes of the foregoing determination, a “cashless exercise” of the Warrants) as determined by Company Counsel pursuant
to a written opinion letter to such effect, addressed and delivered to, and reasonably acceptable to, the Transfer Agent (the “Effectiveness
Period”). The Company shall notify the Purchaser via fax transmission or electronic mail of the effectiveness of a Registration
Statement prior to 9:00 A.M. New York City time on the first Trading Day after the Effective Date. The Company shall, by 9:30 A.M.
New York City time on the first Trading Day after the Effective Date, file a final Prospectus with the Commission, as required
by Rule 424(b).

 

(c)          
If: (i) the Initial Registration Statement is not filed with the Commission on or prior to the Filing Deadline, (ii) the
Initial Registration Statement or the New Registration Statement, as applicable, is not declared effective by the Commission (or
otherwise does not become effective) for any reason on or prior to the Effectiveness Deadline, (iii) after its Effective Date,
(A) such Registration Statement ceases for any reason (including, without limitation, by reason of a stop order, or the Company’s
failure to update the Registration Statement) to remain continuously effective as to all Registrable Securities included in such
Registration Statement or (B) the Purchaser is not permitted to utilize the Prospectus therein to resell such Registrable
Securities (in each case of (A) and (B), other than during an Allowable Suspension Period), or (iv) after the date that
is six months following the Closing Date, and only in the event a Registration Statement is not effective or available to sell
all Registrable Securities, the Company fails to file with the Commission any required reports under Section 13 or 15(d) of
the Exchange Act such that it is not in compliance with Rule 144(c)(1) as a result of which Purchaser who is not an affiliate is
unable to sell Registrable Securities without restriction under Rule 144 (any such failure or breach in clauses (i) through
(iv) above being referred to as an “Event,” and the date on which such Event occurs being referred to as
an “Event Date”), then in addition to any other rights Purchaser may have hereunder or under applicable law,
the Company shall pay to the Purchaser, as partial liquidated damages and not as a penalty (“Registration Delay Payments”),
(1) on each such Event Date, an amount in cash equal to two percent (2.0%) of the aggregate purchase price paid by the Purchaser
pursuant to the Purchase Agreement for any unregistered Registrable Securities held by Purchaser on the Event Date, and (2) on
each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable
Event is cured, an amount in cash equal to two percent (2.0%) of the aggregate purchase price paid by the Purchaser pursuant
to the Purchase Agreement for any unregistered Registrable Securities held by Purchaser on the Event Date. The parties agree that,
notwithstanding anything to the contrary herein or in the Purchase Agreement, (1) no Registration Delay Payments shall be payable
(x) if, as of the relevant Event Date, the Registrable Securities may be sold by non-affiliates without volume or manner of
sale restrictions under Rule 144 and the Company is in compliance with the current public information requirements under Rule 144,
as determined by Company Counsel pursuant to a written opinion letter to such effect, addressed and delivered to, and reasonably
acceptable to the Transfer Agent, or (y) with respect to any period after the expiration of the Effectiveness Period (it being
understood that this clause shall not relieve the Company of any Registration Delay Payments accruing prior to the expiration of
the Effectiveness Period), (2) in no event shall the aggregate amount of Registration Delay Payments payable to the Purchaser exceed,
in the aggregate, ten percent (10%) of the aggregate purchase price paid by the Purchaser pursuant to the Purchase
Agreement, and (3) in no event shall the Company be liable in any thirty (30) day period for Registration Delay Payments
under this Agreement in excess of two percent (2.0%) of the aggregate purchase price paid by the Purchaser pursuant to the
Purchase Agreement. If the Company fails to pay any Registration Delay Payments pursuant to this Section 2(c) in full
within five Business Days after the date payable, the Company will pay interest thereon at a rate of one and one-half percent (1.5%) per
month (or such lesser maximum amount that is permitted to be paid by applicable law) to the Purchaser, accruing daily from the
date such Registration Delay Payments are due until such amounts, plus all such

 

    	4

    	 

    

 

interest
thereon, are paid in full. The Registration Delay Payments pursuant to the terms hereof shall apply on a daily pro-rata basis
for any portion of a month prior to the cure of an Event, except in the case of the first Event Date. The Company shall not be
liable for Registration Delay Payments under this Agreement as to any Registrable Securities which are not permitted by the Commission
to be included in a Registration Statement due solely to SEC Guidance from the time that it is determined that such Registrable
Securities are not permitted to be registered until such time as the provisions of this Agreement as to a Remainder Registration
Statement required to be filed hereunder are triggered, in which case the provisions of this Section 2(c) shall once
again apply, if applicable. In such case, the Registration Delay Payments shall be calculated to only apply to the percentage
of Registrable Securities which are permitted in accordance with SEC Guidance to be included in such Registration Statement. With
respect to the Purchaser failing to timely provide the Company with information requested by the Company and necessary to complete
the Registration Statement in accordance with the requirements of the Securities Act, the Effectiveness Deadline for a Registration
Statement shall be extended without default or Registration Delay Payments hereunder in the event that the Company’s failure
to obtain the effectiveness of the Registration Statement on a timely basis results from the failure of the Purchaser to timely
provide the Company with such information.

 

(d)         
Purchaser agrees to furnish to the Company a completed Selling Stockholder Questionnaire not more than 10 Trading Days following
the date of this Agreement. Purchaser further agrees that it shall not be entitled to be named as a selling security holder in
the Registration Statement or use the Prospectus for offers and resales of Registrable Securities at any time, unless Purchaser
has returned to the Company a completed and signed Selling Stockholder Questionnaire. If Purchaser returns a Selling Stockholder
Questionnaire after its deadline, the Company shall use its commercially reasonable efforts to take such actions as are required
to name Purchaser as a selling security holder in the Registration Statement or any pre-effective or post-effective amendment thereto
and to include (to the extent not theretofore included) in the Registration Statement the Registrable Securities identified in
such late Selling Stockholder Questionnaire. Purchaser acknowledges and agrees that the information in the Selling Stockholder
Questionnaire as described in this Section 2(d) will be used by the Company in the preparation of the Registration
Statement and hereby consents to the inclusion of such information in the Registration Statement.

 

(e)          
Purchaser acknowledges that Form S-3 is not available for the registration of the resale of Registrable Securities hereunder
as of the date of this Agreement. As such, the Company shall (i) register the resale of the Registrable Securities on another appropriate
form and (ii) undertake to register the Registrable Securities on Form S-3 promptly after such form is available; provided
that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration
Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.

 

		3.	Registration Procedures. In connection with the
Company’s registration obligations hereunder:

 

(a)          
The Company shall, not less than three Trading Days prior to the filing of each Registration Statement and not less than
one Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto (except for Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any similar or successor reports), (i) furnish
to the Purchaser copies of such Registration Statement, Prospectus or amendment or supplement thereto, as proposed to be filed,
which documents will be subject to the review of Purchaser (it being acknowledged and agreed that if Purchaser does not object
to or comment on the aforementioned documents within such three Trading Day or one Trading Day period, as the case may be, then
Purchaser shall be deemed to have consented to and approved the use of such documents) and (ii) use commercially reasonable
efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries
as shall be necessary, in the reasonable opinion of respective counsel to Purchaser, to conduct a reasonable review.

 

(b)          
(i) The Company shall prepare and file with the Commission such amendments (including post-effective amendments) and supplements,
to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement
continuously effective as to the applicable Registrable Securities for its Effectiveness Period; (ii) the Company shall cause
the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement),
and, as so supplemented or amended, to be filed pursuant to Rule 424; (iii) the Company shall respond as promptly as reasonably
practicable to any comments received from the Commission with respect to each Registration Statement or any amendment thereto and,
as promptly as reasonably practicable, provide the Purchaser true and complete

 

    	5

    	 

    

 

copies
of all correspondence from and to the Commission relating to such Registration Statement that pertains to the Purchaser as “Selling
Stockholders” but not any comments that would result in the disclosure to the Purchaser of material and non-public information
concerning the Company; and (iv) the Company shall comply in all material respects with the provisions of the Securities
Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement until
such time as all of such Registrable Securities shall have been disposed of (subject to the terms of this Agreement) in accordance
with the intended methods of disposition by the Purchaser thereof as set forth in such Registration Statement as so amended or
in such Prospectus as so supplemented; provided, however, that the Purchaser shall be responsible for the delivery of the Prospectus
to the Persons to whom the Purchaser sells any of the Registrable Securities (including in accordance with Rule 172 under the
Securities Act), and the Purchaser agrees to dispose of Registrable Securities in compliance with the “Plan of Distribution”
described in the Registration Statement and otherwise in compliance with applicable federal and state securities laws. In the
case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including
pursuant to this Section 3(b) by reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any
analogous report under the Exchange Act, the Company shall have incorporated such report by reference into such Registration Statement,
if applicable, or shall file such amendments or supplements with the Commission on the same day on which the Exchange Act report
which created the requirement for the Company to amend or supplement such Registration Statement was filed.

 

(c)          
The Company shall notify the Purchaser (which notice shall, pursuant to clauses (iii) through (v) hereof, be accompanied
by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably practicable
(and, in the case of (i)(A) below, not less than one Trading Day prior to such filing): (i)(A) when a Prospectus or any Prospectus
supplement or post-effective amendment to a Registration Statement is proposed to be filed; (B) when the Commission notifies
the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in
writing on any Registration Statement (in which case the Company shall provide to each of the Purchaser true and complete copies
of all comments that pertain to the Purchaser as a “Selling Stockholder” or to the “Plan of Distribution”
and all written responses thereto, but not information that the Company believes would constitute material and non-public information);
and (C) with respect to each Registration Statement or any post-effective amendment, when the same has become effective; (ii) of
any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
Statement or Prospectus or for additional information that pertains to the Purchaser as “Selling Stockholder” or the
“Plan of Distribution”; (iii) of the issuance by the Commission or any other federal or state governmental authority
of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or
the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to
the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction,
or the initiation or threatening of any Proceeding for such purpose; and (v) of the occurrence of any event or passage of
time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement
made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference
untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other documents so
that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
(in the case of any Prospectus, form of prospectus or supplement thereto, in light of the circumstances under which they were made)
not misleading.

 

(d)          
The Company shall use commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of
(i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or
exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable.

 

(e)          
The Company shall, if requested by Purchaser, furnish to Purchaser, without charge, at least one conformed copy of each
Registration Statement and each amendment thereto and all exhibits to the extent requested by such Person (including those previously
furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that the Company
shall have no obligation to provide any document pursuant to this clause that is available on the Commission’s EDGAR system.

 

    	6

    	 

    

 

(f)          
The Company shall, prior to any resale of Registrable Securities by Purchaser, use its commercially reasonable efforts to
register or qualify or cooperate with the selling Purchaser in connection with the registration or qualification (or exemption
from the registration or qualification) of such Registrable Securities for the resale by Purchaser under the securities or blue
sky laws of such jurisdictions within the United States as Purchaser reasonably requests in writing, to keep each registration
or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things
reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration
Statement; provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is
not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file
a general consent to service of process in any such jurisdiction.

 

(g)          
If requested by Purchaser, the Company shall cooperate with Purchaser to facilitate the timely preparation and delivery
of certificates representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which
certificates shall be free of all restrictive legends, and to enable such Registrable Securities to be in such denominations and
registered in such names as Purchaser may reasonably request. Notwithstanding the foregoing, upon Purchaser’s request, certificates
for Registrable Securities free from all restrictive legends shall instead be transmitted by the Transfer Agent to Purchaser by
crediting the account of Purchaser’s prime broker with DTC as directed by Purchaser.

 

(h)          
The Company shall, following the occurrence of any event contemplated by Section 3(c), as promptly as reasonably
practicable (taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders
of the premature disclosure of such event), prepare and file a supplement or amendment, including a post-effective amendment, to
the affected Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated
therein by reference, and file any other required document so that, as thereafter delivered, no Registration Statement nor any
Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein (in the case of any Prospectus, form of prospectus or supplement thereto, in light of
the circumstances under which they were made) not misleading.

 

(i)          
The Company may require Purchaser to furnish to the Company a certified statement as to (i) the number of shares of
Common Stock beneficially owned by Purchaser and any Affiliate thereof, (ii) any Financial Industry Regulatory Authority (“FINRA”)
affiliations, (iii) any natural persons who have the power to vote or dispose of any shares of Common Stock beneficially owned
by Purchaser and any Affiliate thereof, and (iv) any other information as may be requested by the Commission, FINRA or any
state securities commission. During any periods that the Company is unable to meet its obligations hereunder with respect to the
registration of Registrable Securities because Purchaser fails to furnish such information within three (3) Trading Days of
the Company’s request, any Registration Delay Payments that are accruing at such time as to Purchaser only shall be tolled
and any Event that may otherwise occur solely because of such delay shall be suspended as to Purchaser only, until such information
is delivered to the Company.

 

(j)          
The Company shall cooperate with any registered broker-dealer through which Purchaser proposes to make sales of its Registrable
Securities in effecting such broker-dealer’s filing with FINRA pursuant to FINRA Rule 5110, as reasonably requested by Purchaser,
and the Company shall pay the filing fee required for the first such filing within two (2) Business Days of the request therefor
(so long as the broker-dealer is receiving no more than a customary brokerage commission in connection with such sales).

 

(k)         
The Company agrees to deliver promptly to Purchaser, without charge, as many copies of each Prospectus (including each form
of prospectus) and each amendment or supplement thereto as Purchaser may reasonably request.

 

(l)          
The Company shall make available to its security holders, as soon as reasonably practicable, but not later than the Availability
Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after the effective
date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities
Act, including Rule 158 promulgated thereunder (for the purpose of this Section 3(m), “Availability Date”
means the 45th day following the end of the fourth fiscal quarter that includes the effective date of such Registration Statement,
except that, if such fourth fiscal quarter is the

 

    	7

    	 

    

 

last
quarter of the Company’s fiscal year, “Availability Date” means the 90th day after the end of such fourth
fiscal quarter).

 

4.          
Registration Expenses. All fees and expenses incident to the Company’s performance of or compliance with its
obligations under this Agreement (excluding any underwriting discounts and selling commissions and all legal fees and expenses
of legal counsel for Purchaser) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a
Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all
registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to be
made with any Trading Market on which the Common Stock is then listed or quoted for trading, and (B) with respect to compliance
with applicable state securities or blue sky laws (including, without limitation, fees and disbursements of Company Counsel in
connection with blue sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without
limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses,
(iv) fees and disbursements of Company Counsel, (v) Securities Act liability insurance, if the Company so desires such
insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of
the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses
incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation,
all salaries and expenses of its officers and employees performing legal or accounting duties) and the expense of any annual audit.
In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of Purchaser or, except
to the extent provided for in the Transaction Documents, any legal fees or other costs of the Purchaser.

 

		5.	Indemnification.

 

(a)          
Indemnification by the Company. The Company shall indemnify, defend and hold harmless Purchaser, its officers, directors,
agents, partners, members, managers, stockholders, Affiliates and employees, each Person who controls any Purchaser (within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, partners,
members, managers, stockholders, agents and employees of each such controlling Person, to the fullest extent permitted by applicable
law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs
of preparation and investigation and reasonable attorneys’ fees) and expenses (collectively, “Losses”),
as incurred, that arise out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in
any Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein
or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light
of the circumstances under which they were made) not misleading, or (ii) any violation or alleged violation by the Company
of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the performance
of its obligations under this Agreement, except to the extent, but only to the extent, that (A) such untrue statements, alleged
untrue statements, omissions or alleged omissions are based solely upon information regarding Purchaser furnished in writing to
the Company by Purchaser expressly for use therein, or to the extent that such information relates to Purchaser or Purchaser’s
proposed method of distribution of Registrable Securities and was reviewed and approved in writing by Purchaser expressly for use
in the Registration Statement, such Prospectus or such form of prospectus or in any amendment or supplement thereto (it being understood
that Purchaser has approved Annex A hereto for this purpose) or (B) in the case of an occurrence of an event of the
type specified in Section 3(c)(iii)-(v), Purchaser uses an outdated or defective Prospectus after the Company has notified
Purchaser in writing that the Prospectus is outdated or defective and prior to the receipt by Purchaser of the Advice contemplated
in Section 6(d) below or (C) any such Losses arise out of Purchaser’s (or any other indemnified Person’s)
failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented), if required, pursuant to Rule
172 under the Securities Act (or any successor rule) to the Persons asserting an untrue statement or alleged untrue statement or
omission or alleged omission at or prior to the written confirmation of the sale of Registrable Securities to such Person if such
statement or omission was corrected in such Prospectus or supplement. The Company shall notify the Purchaser promptly of the institution
of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware.
Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of an Indemnified Party
(as defined in Section 5(c)) and shall survive the transfer of the Registrable Securities by the Purchaser.

 

    	8

    	 

    

 

(b)          
Indemnification by Purchaser. Purchaser shall indemnify and hold harmless the Company, its directors, officers, agents,
stockholders, Affiliates and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, stockholders, agents or employees of such controlling
Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, that arise out of or are
based upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or
any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating
to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
(in the case of any Prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they
were made) not misleading (i) to the extent that such untrue statements, alleged untrue statements, omissions or alleged omissions
are based solely upon information regarding Purchaser furnished in writing to the Company by Purchaser expressly for use therein
or (ii) to the extent that such information relates to Purchaser or Purchaser’s proposed method of distribution of Registrable
Securities and was reviewed and approved in writing by Purchaser expressly for use in a Registration Statement, such Prospectus
or such form of prospectus or in any amendment or supplement thereto (it being understood that Purchaser has approved Annex
A hereto for this purpose) or (iii) in the case of an occurrence of an event of the type specified in Section 3(c)(iii)-(v),
to the extent Purchaser uses an outdated or defective Prospectus after the Company has notified Purchaser in writing that the Prospectus
is outdated or defective and prior to the receipt by Purchaser of the Advice contemplated in Section 6(d). In no event
shall the liability of Purchaser hereunder be greater in amount than the dollar amount of the net proceeds received by Purchaser
upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)          
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled
to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from
whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right
to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment
of all reasonable fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified
Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities under this Section 5,
except (and only) to the extent that such failure shall have materially and adversely prejudiced the Indemnifying Party.

 

An Indemnified Party
shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees
and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the defense
of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the
named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest exists if the same counsel were
to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying
Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall
not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party); provided,
that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time
for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without
its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying Party shall, without
the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified
Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding.

 

Subject to the terms
of this Agreement, all fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred
in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section 5)
shall be paid to the Indemnified Party, as incurred, within 20 Trading Days of written notice thereof to the Indemnifying
Party; provided, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses
applicable to such actions for which such Indemnified Party is finally judicially determined to not be entitled to indemnification
hereunder).

 

    	9

    	 

    

 

(d)          
Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified
Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying
such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in
such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with
the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative
fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action
in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material
fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The
amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in
this Agreement, any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with
any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for
in this Section 5 was available to such party in accordance with its terms.

 

The parties hereto
agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in
the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), (i) Purchaser shall
not be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received
by Purchaser from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that Purchaser
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and (ii) no
contribution will be made under circumstances where the maker of such contribution would not have been required to indemnify the
Indemnified Party under the fault standards set forth in this Section 5. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not
guilty of such fraudulent misrepresentation.

 

The indemnity and contribution
agreements contained in this Section 5 are in addition to any liability that the Indemnifying Parties may have to the
Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Purchase Agreement.

 

6.           
Miscellaneous.

 

(a)          
Remedies. In the event of a breach by the Company or by Purchaser of any of their obligations under this Agreement,
Purchaser or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this
Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company
and Purchaser agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach
by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall waive the defense that a remedy at law would be adequate.

 

(b)          
Compliance. Purchaser covenants and agrees that it will comply with the prospectus delivery requirements of the Securities
Act as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant
to the Registration Statement and shall sell the Registrable Securities only in accordance with a method of distribution described
in the Registration Statement.

 

(c)          
Discontinued Disposition. By its acquisition of Registrable Securities, Purchaser agrees that, upon receipt of a
notice from the Company of the occurrence of any event of the kind described in Section 3(c)(iii)-(v), Purchaser will
forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing
(the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or
amended) may be resumed. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may
be resumed as promptly as is practicable. Notwithstanding any provision herein to the contrary, the Company shall be entitled to
exercise its right under this Section 6(c) to suspend the availability of a Registration Statement and Prospectus,
subject to the payment of partial Registration Delay Payments otherwise required pursuant to Section 2(c), for a period
not to exceed

 

    	10

    	 

    

 

20 consecutive
calendar days or 60 calendar days (which need not be consecutive days) in any 12 month period (each suspension period
complying with this provision, an “Allowable Suspension Period”).

 

(d)          
Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, or waived unless the same shall be in writing and signed by the Company and Purchaser.

 

(e)          
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be delivered as set forth in the Purchase Agreement.

 

(f)          
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties and shall inure to the benefit of Purchaser. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations,
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may not assign
its rights or obligations hereunder without the prior written consent of Purchaser, except in the event of a merger or in connection
with another entity acquiring all or substantially all of the Company’s assets. Purchaser may not assign its rights or obligations
hereunder other than to an entity in which Purchaser maintains a majority equity ownership position without the prior written consent
of the Company, except in the event of a merger or in connection with another entity acquiring all or substantially all of the
Purchaser’s assets.

 

(g)          
Execution and Counterparts. This Agreement may be executed in two or more counterparts, each of which when so executed
shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
were the original thereof.

 

(h)         
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be determined in accordance with the provisions of the Purchase Agreement.

 

(i)          
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided
by law.

 

(j)          
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their good faith reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

(k)          
Headings. The headings in this Agreement are for convenience only and shall not limit or otherwise affect the meaning
hereof.

  

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	11

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Registration Right Agreement to be duly executed as of the date first indicated above.

  

MRI Interventions,
Inc.

  

	By: 	 	 
	Name: Harold A. Hurwitz	 
	Title: Chief Financial Officer	 

  

BRAINLAB AG

 

	By:	 	 	 	 
	Name:	 	 
	Title:	 	 	 
	 	 	 	 	 

 

    	 

    	 

    

 

ANNEX A

 

PLAN OF DISTRIBUTION

 

The selling securityholder,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests
in shares of common stock received after the date of this prospectus from the selling securityholder as a gift, pledge, partnership
distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common
stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling securityholder
may use any one or more of the following methods when disposing of shares or interests therein:

 

		·	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		·	block trades in which the broker-dealer will attempt to sell the shares as agent, but may position
and resell a portion of the block as principal to facilitate the transaction;

 

		·	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		·	an exchange distribution in accordance with the rules of the applicable exchange;

 

		·	privately negotiated transactions;

 

		·	settlement of short sales;

 

		·	through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;

 

		·	broker-dealers may agree with the selling securityholder to sell a specified number of such shares
at a stipulated price per share;

 

		·	a combination of any such methods of sale; and

 

		·	any other method permitted by applicable law.

 

The selling securityholder
may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b) or other applicable
provision of the Securities Act amending the list of selling securityholder to include the pledgee, transferee or other successors-in-interest
as selling securityholder under this prospectus. The selling securityholder also may transfer the shares of common stock in other
circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for
purposes of this prospectus.

 

In connection with
the sale of our common stock or interests therein, the selling securityholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling securityholder may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
securityholder may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

    	Annex A

    	 

    

 

The aggregate proceeds
to the selling securityholder from the sale of the common stock offered by them will be the purchase price of the common stock
less discounts or commissions, if any. The selling securityholder reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.
We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will
receive the exercise price of the warrants.

 

The selling securityholder
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of
1933, provided that they meet the criteria and conform to the requirements of that rule.

 

The selling securityholder
and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters”
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. A selling securityholder who is an “underwriter”
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.

 

To the extent required,
the shares of our common stock to be sold, the name of the selling securityholder, the respective purchase prices and public offering
prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular
offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration
statement that includes this prospectus.

 

In order to comply
with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.

 

We have advised the
selling securityholder that the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934 may apply to
sales of shares in the market and to the activities of the selling securityholder and their affiliates. In addition, to the extent
applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling
securityholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling securityholder
may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities,
including liabilities arising under the Securities Act.

 

We have agreed to indemnify
the selling securityholder against liabilities, including liabilities under the Securities Act and state securities laws, relating
to the registration of the shares offered by this prospectus.

 

We have agreed with the selling securityholder
to keep the registration statement of which this prospectus constitutes a part effective until the earlier of: (1) such time as
all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement;
or (2) the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act.

 

    	Annex A

    	 

    

 

ANNEX B

 

SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE

 

Purchaser, the holder
of shares of the common stock, par value $0.01 per share, of MRI Interventions, Inc. (the “Company”) issued
pursuant to a certain Securities Purchase Agreement by and between the Company and the Purchaser named therein, dated as of March
22, 2016, understands that the Company intends to file with the Securities and Exchange Commission a registration statement (the
“Resale Registration Statement”) for the registration and the resale under Rule 415 of the Securities Act of
1933, as amended (the “Securities Act”), of the Registrable Securities in accordance with the terms of that
certain Registration Rights Agreement by and between the Company and the Purchaser named therein, dated as of April 4, 2016 (the
“Agreement”). All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in
the Agreement.

 

In order to sell or
otherwise dispose of any Registrable Securities pursuant to the Resale Registration Statement, Purchaser generally will be required
to be named as a selling securityholder in the related prospectus or a supplement thereto (as so supplemented, the “Prospectus”),
deliver the Prospectus to purchasers of Registrable Securities (including pursuant to Rule 172 under the Securities Act) and be
bound by the provisions of the Agreement (including certain indemnification provisions, as described below). Purchaser must complete
and deliver this Notice and Questionnaire in order to be named as a selling securityholder in the Prospectus.

 

Certain legal consequences
arise from being named as a selling stockholder in the Resale Registration Statement and the Prospectus. Purchaser is advised to
consult their own securities law counsel regarding the consequences of being named or not named as a selling stockholder in the
Resale Registration Statement and the Prospectus.

 

NOTICE

 

Purchaser hereby gives
notice to the Company of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item
(3), unless otherwise specified in Item (3), pursuant to the Resale Registration Statement. The undersigned, by signing and returning
this Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire
and the Agreement.

 

The undersigned hereby
provides the following information to the Company and represents and warrants that such information is accurate and complete:

 

    	Annex B

    	 

    

 

QUESTIONNAIRE

 

		1.	Name:

 

(a)          Full Legal Name of Purchaser:

 

Brainlab AG

 

(b)           Full Legal Name of Purchaser (if not the same
as (a) above) through which Registrable Securities Listed in Item 3 below are held:

  

 

 

(c)           Full Legal Name of Natural Control Person (which
means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by
the questionnaire):

  

 

 

		2.	Address for Notices to Purchaser:

 

General Counsel and Director Legal

  

Kapellenstrasse 12, 85622 Feldkirchen, Germany

 

Telephone:+4989991568-0

 

Fax:+4989991568-33

 

Contact Person: Michaela Oberrecht

 

E-mail address of Contact Person: michaela.oberrecht-heusler@brainlab.com

 

		3.	Beneficial Ownership of Registrable Securities Issuable
Pursuant to the Purchase Agreement:

  

(a)          Type and Number of Registrable Securities beneficially
owned and issued pursuant to the Agreement:

  

(i) 3,972,410 shares of Common Stock; (ii) one Warrant
to purchase 1,588,964 Warrant Shares (“A Warrant”); and (iii) one Warrant to purchase 1,191,723 Warrant Shares (“B
Warrant”)

  

(b)          Number of shares of Common Stock to be registered
pursuant to this Notice for resale:

 

6,753,097

 

		4.	Broker-Dealer Status:

 

(a)          Are you a broker-dealer?

  

Yes    ☐       
  No    ☒

 

    	Annex B

    	 

    

 

(b)          If “yes” to Section
4(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?

  

Yes    ☐       
 No    ☐

 

 Note: If no, the
Commission’s staff has indicated that you should be identified as an underwriter in the Resale Registration Statement.

  

(c)          Are
you an affiliate of a broker-dealer?

 

Yes    ☐       
 No    ☒

 

Note: If yes, provide a narrative explanation
below:

	 
	 
	 

  

(d)          If you
are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or
indirectly, with any person to distribute the Registrable Securities?

 

Yes    ☐       
 No    ☐

 

Note: If no, the
Commission’s staff has indicated that you should be identified as an underwriter in the Resale Registration Statement.

  

		5.	Beneficial Ownership of Other Securities of the Company
Owned by Purchaser.

 

Except as set forth
below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than the
Registrable Securities listed above in Item 3.

 

Type and amount of
other securities beneficially owned:

  

SECOND AMENDED AND RESTATED SECURED NOTE DUE 2018 which has
a principal amount of USD $2,000,000

 

		6.	Relationships with the Company:

 

Except as set forth below, neither the
undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities
of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors
or affiliates) during the past three years.

 

State any exceptions here: 

 

Brainlab, represented by Ken Bruener, VP of Marketing and Business
Development IGS North America, holds a board observer position at MRI Interventions. 

 

MRI Interventions is a supplier of Brainlab for products in
its drug delivery business.

 

    	Annex B

    	 

    

 

Brainlab is a creditor of MRI Interventions due to the above
mentioned note. 

 

		7.	Plan of Distribution:

 

The undersigned
has reviewed the form of Plan of Distribution attached as Annex A to the Registration Rights Agreement, and hereby confirms that,
except as set forth below, the information contained therein regarding the undersigned and its plan of distribution is correct
and complete.

  

State any exceptions
here: 

	 
	 

  

***********

 

Purchaser agrees to
promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof and prior to the effective date of any applicable Resale Registration Statement. All notices hereunder shall be made
pursuant to the terms of the Agreement. In the absence of any such notification, the Company shall be entitled to continue to rely
on the accuracy of the information in this Notice and Questionnaire.

 

By signing below, Purchaser
consents to the disclosure of the information contained herein in its answers to Items (1) through (7) above and the
inclusion of such information in the Resale Registration Statement and the Prospectus. The undersigned understands that such information
will be relied upon by the Company in connection with the preparation or amendment of the Resale Registration Statement and the
Prospectus.

 

By signing below, Purchaser
acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions of the Exchange
Act and the rules and regulations thereunder, particularly Regulation M in connection with any offering of Registrable Securities
pursuant to the Resale Registration Statement. Purchaser also acknowledges that it understands that the answers to this Questionnaire
are furnished for use in connection with Registration Statements filed pursuant to the Registration Rights Agreement and any amendments
or supplements thereto filed with the Commission pursuant to the Securities Act.

 

Purchaser confirms
that, to the best of its knowledge and belief, the foregoing statements (including without limitation the answers to this Questionnaire)
are correct and complete.

 

IN WITNESS WHEREOF,
Purchaser has caused this Questionnaire to be executed and delivered either in person or by its duly authorized agent.

 

	Dated:                     , 2016	BRAINLAB AG
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	Annex BPATENT AND TECHNOLOGY LICENSE AGREEMENT

 

THIS PATENT AND
TECHNOLOGY LICENSE AGREEMENT (“Agreement”), dated and effective as of April 4, 2016 (“Effective
Date”) is entered into by and among MRI Interventions, Inc., having a place of business at 5 Musick, Irvine, CA 92618
(“Licensor”) and Brainlab AG, having a place of business at Kapellenstraße 12, 85622 Feldkirchen, Germany
(“Licensee”).

 

WHEREAS, Licensor
owns or holds rights in certain intellectual property and rights therein relating to certain medical technology intended to provide
stereotactic guidance for the frameless placement and operation of instruments or devices during planning and operation of neurological
procedures, such as deep brain stimulation, biopsies or catheter placements, and desires to grant to Licensee a license to the
intellectual property and rights therein;

 

WHEREAS, Licensee
desires to obtain a license from Licensor to the intellectual property related to the ClearPoint Software, so that Licensee can
develop its own software to work in conjunction with the SmartFrame Products for stereotactic guidance for the frameless placement
and operation of instruments or devices during planning and operation of neurological procedures, such as deep brain stimulation,
biopsies or catheter placements, and rights therein;

 

WHEREAS,
both parties acknowledge that said license is only to the Licensed Patents and Intellectual Property related to the ClearPoint
Software, to make, have made, use, offer to sell, sell, have sold, import and export Brainlab software, either alone or in combination
with the SmartFrame Products, that supports and works with the SmartFrame Products, and does not
grant any rights to the SmartFrame Products themselves, other than rights to utilize the dimensions and technical specifications
of the SmartFrame Products as needed to make the software functional and the right to utilize the Intellectual Property to market
the Brainlab software, either alone or in combination with the SmartFrame Products;

 

WHEREAS, both
parties acknowledge no license is granted to make, market or sell any SmartFrame Products other than the marketing of the SmartFrame
Products incidental to or in combination with the Brainlab software.

 

NOW, THEREFORE,
in consideration of the foregoing and the respective promises and covenants contained in this Agreement, Licensor and Licensee
hereby agree as follows:

 

		1.	Definitions.

 

The following
terms shall have the meanings set forth below:

 

1.1             
Affiliate. “Affiliate” shall have the meaning ascribed to such term under Rule 405 of the
Securities Act of 1933.

 

1.2            
ClearPoint Software. means Licensee’s ClearPoint Software, which works with the SmartFrame Products;
all associated iterations and future versions thereof, or other software products that are either substantially similar thereto
or that are covered by or that use, incorporate or contains processes or methods that are described in, relate to, or are covered
by (i) one or more valid and enforceable, issued or pending claims of the Licensed Patents and/or (ii) other Intellectual Property.

 

1.3            
Improvements. “Improvements” means any and all modifications, corrections and/or improvements
to the Patents, Licensor Know-how, Licensee Know-how and/or Technology, as the case may be, developed by either Licensor or Licensee,
embodied in or necessary to create a functional alternative of the ClearPoint Software.

 

    	 

    	 

    

 

1.4              Intellectual
Property. “Intellectual Property” means the Licensor Improvements, Licensor Know-how, Licensor
Technology, and Licensor Data embodied in or necessary to create a functional alternative of the ClearPoint Software as well as
the trademarks, service marks and trade names of the SmartFrame Products.

 

1.5             
Licensed Patents. “Licensed Patents” means the Patents.

 

1.6             
Licensee Know-how. “Licensee Know-how” means know-how owned or controlled by Licensee related
to or utilized by the ClearPoint Software.

 

1.7              Licensor Data. “Licensor Data” means all data obtained by Licensor regarding any product
studies, test results and independent focus group studies for all applications and uses of the Technology.

 

1.8              Licensor
Know-how. “Licensor Know-how” means know-how owned or controlled by Licensor, including the Know-how identified
on Schedule 1.8 attached hereto, embodied in or necessary to create a functional alternative to the ClearPoint Software.

 

1.9            
Patents. “Patents” means all United States patents and all corresponding worldwide patents, and
the applications on which said patents issue, including all parents, continuations, continuations-in part, divisionals, reissues,
reexamination certificates, extensions and renewals thereto in which Licensor has any rights related to the ClearPoint Software,
including, without limitation, those identified on Schedule 1.9 attached hereto.

 

1.10          
Person. “Person” means an individual, a corporation, a partnership, an association, a limited
liability company, a trust, any unincorporated organization or a government or a political subdivision thereof.

 

1.11          
SmartFrame Products. “SmartFrame Products” means Licensee’s SmartFrame products,
all associated accessories and future versions thereof or other products that are substantially similar thereto, which are utilized
with the ClearPoint Software for stereotactic guidance of neurological procedures, such as deep brain stimulation, laser ablation,
biopsies or catheter placements, including, without limitation, those identified on Exhibit 1 of Attachment A: Exchange of Technical
Data Agreement attached hereto.

  

1.12          
Technology. “Technology” means any and all inventions, Improvements, engineering drawings,
test specifications, technical manuals, technical data, Confidential Information, materials, trade secrets, technology, formulas,
processes, and ideas in any form in which the foregoing may exist, that is owned or controlled by Licensor embodied in or necessary
to create a functional alternative to the ClearPoint Software.

 

		2.	Licenses.

 

2.1            
Licensed Patents Grant. Subject to Licensor’s rights under the terms of this Agreement and subject to
an event triggering a Termination pursuant to Article 5, Licensor grants Licensee a worldwide, perpetual (with respect to the Intellectual
Property and with respect to the Patents for the life of the Patents) irrevocable, non-exclusive license to use the Licensed Patents
and Intellectual Property to make, have made, use, offer to sell, sell, have sold, import and export Brainlab software that supports
and works with the SmartFrame Products and to develop software Improvements and other software products and software services to
support or work with the SmartFrame Products based on the Licensed Patents

 

    	2

    	 

    

 

and
Intellectual Property. Licensor also grants Licensee the right to grant sub-licenses as set forth in Section 2.2 below.
This license shall not allow Brainlab to incorporate the Licensed Patents and Intellectual Property into any other product. Notwithstanding
anything to the contrary contained herein, in the event of any termination of this Agreement for any reason whatsoever, such termination
shall have no adverse impact on any licenses provided to end users prior to such termination in connection with the purchase of
products utilizing the Intellectual Property or the Licensed Patents. For the avoidance of doubt, both parties acknowledge that
this License Grant does not grant any rights to the SmartFrame Products themselves, other than rights to utilize the dimensions
and technical specifications of the SmartFrame Products as needed to make the software functional and the right to utilize the
Intellectual Property to market the Brainlab software, either alone or in combination with the SmartFrame Products; in addition,
both parties acknowledge no license is granted to make, market or sell any SmartFrame Products other than the marketing of the
SmartFrame Products incidental to or in combination with the Brainlab software.

 

2.2             
Sublicenses. Licensee shall have the right to grant one or more sub-licenses under the Licensed Patents and
Intellectual Property to use Licensed Patents and Intellectual Property to Affiliates and subsidiaries, of Brainlab AG, with the
same rights and limitation as Licensee is granted under this Agreement.

 

2.3             
Consideration. The consideration for the license and other rights granted to Licensee by Licensor hereunder shall
be Licensee’s willingness to enter into that certain Second Amended and Restated Secured Note Due 2018 dated as of even date
herewith (the “Note”). Upon execution and delivery by Licensee of the Note, the consideration shall be paid
in full and Licensor hereby agrees and acknowledges that the execution and delivery of the Note by Licensee constitute adequate
consideration for the obligations of Licensor hereunder.

 

3.           
Taxes. Licensor is not responsible for any sales, use, value-added, personal property or other taxes
imposed on either Licensee’s or any sub-licensees’ use, possession, offer for sale, or sale of any products, whether
or not developed in relation to the Licensed Patents or Intellectual Property. Each party shall be solely responsible for any taxes
based on its own net income.

 

4.           
Licensor Support. Licensor shall, at no further cost to Licensee, use commercially reasonable efforts
to provide up to 100 hours of technical support to Licensee as reasonably requested by Licensee, with a development project for
Licensee to develop its own software products to support and work with the SmartFrame Products, including, without limitation by
(i) entering into the Exchange of Technical Data Agreement attached hereto as Exhibit A, (ii) supporting Licensee’s
development efforts and (iii) supporting Licensee’s efforts regarding validation testing. In the event that Licensor makes
changes to the SmartFrame Products subsequent to Brainlab’s development of its supportive software that require Brainlab
to undertake further development, Licensor shall, at no further cost to Licensee, use commercially reasonable efforts to provide
up to 100 hours of technical support to Licensee as reasonably requested by Licensee to complete such updated development. Time
requests beyond 100 hours shall be considered by the parties, and MRII shall make reasonable efforts to provide such support at
the following agreed upon annual rate (subject to increase each year by an amount not to exceed the increase in the US consumer
price index):

 

	Junior Engineer -	$50.00 per hour
	Engineer -	$80.00 per hour
	Head of Product Development -	$120.00 per hour
	Quality Management -	$80.00 per hour

 

    	3

    	 

    

 

		5.	Term and Termination.

 

5.1             
Unless earlier terminated by the Licensor pursuant to this Article, this Agreement shall run from the Effective Date until
the expiration of the last to expire of the Licensed Patents (“Term”).

 

5.2             
Licensor may terminate this Agreement after written notice to Licensee indicating that Licensee has materially breached
any of the terms or conditions of this Agreement, and such breach is not cured within sixty (60) days after receipt of such notice.

 

5.3             
Licensee may terminate this Agreement at any time upon sixty (60) days prior written notice to Licensor.

 

5.4             
Upon termination of this Agreement by either party, Licensee shall within ten (10) days cease all further development of
new products utilizing the Licensed Patents or Intellectual Property; provided that Licensee shall have the right to continue
to support any products based on the Licensed Patents or Intellectual Property already sold to end-users, such as providing updates
to such products as necessary to ensure the safety of such products and its compatibility with other Brainlab software.

 

		6.	Ownership of Rights and Obligations.

 

6.1             
Ownership of Licensed Patents and Licensor Know-how. Licensee acknowledges and agrees that title to and ownership
of the Licensed Patents and Licensor Know-how and all of the applicable intellectual property rights in and to the Licensed Patents
and Licensor Know-how is owned or is exclusively licensed by Licensor or its licensors. Licensee agrees to provide Licensor with
reasonable notice of its sub-licensing of the Licensed Patents to subsidiaries or affiliates (as permitted in Section 2.2).

 

6.2             
Ownership of Improvements. Both parties shall have the right to make Improvements. To the extent that any
Improvements are made or developed independently by a party, they shall be owned by such party, but any Improvements developed
by Licensor shall become subject to this Agreement. To the extent that the Improvements are made or developed jointly by the parties,
such Improvements shall be jointly owned and utilized by the parties (“Joint Improvements”) pursuant to Section
2.3. The filing of any patent applications on Joint Improvements and the allocation of all costs and expenses relating to preparation,
filing, prosecution and maintenance of the resulting patent application and/or patents shall be determined jointly by the Parties.
Should Licensor fail to or choose not to file, prosecute or maintain a patent application and/or patent on Joint Improvements,
Licensee shall have the right, but not the obligation, to prosecute/and or maintain such patent application and/or patents subject
to Licensee paying for and undertaking such obligation to prosecute and maintain any such patents, and Licensor agrees to assign
all right title and interest in and to the patent applications and/or patents resulting from the Joint Improvements for which Licensor
chooses not to file, prosecute or maintain for Joint Improvement and to provide reasonable assistance, at the request of the Licensee
in the prosecution of such patent applications and/or patents; provided however that Licensor shall be given or retain a worldwide,
royalty-free, non-exclusive license to any Joint Improvements, provided that such license shall be non-transferable except in connection
with a sale of all or substantially all of Licensor’s assets.

 

6.3             
Governmental Submissions. All submissions to governmental agencies and other regulatory bodies, including,
without limitation, for purposes of obtaining approvals, licenses or other permissions, is the sole responsibility of Licensee,
and Licensor shall have no obligations relating thereto.

 

    	4

    	 

    

 

		7.	Indemnification.

 

7.1             
Indemnification by Licensor. Licensor shall indemnify, defend and hold harmless Licensee against any claim,
demand or cause of action resulting from a breach of any provision of this Agreement by Licensor, provided, that Licensee
shall promptly notify Licensor upon learning of any such claim, demand or cause of action, and provide Licensor with such assistance
as reasonably requested by Licensor in defending against such claim, demand or cause of action; provided, however,
Licensor will not be released from its indemnification obligations due to Licensee’s failure to give prompt notice of a claim,
except to the extent that Licensor is actually prejudiced by the failure to receive prompt notice of any such claim.

 

7.2             
Indemnification by Licensee. Licensee shall indemnify, hold harmless, and defend Licensor and its officers,
directors, shareholders, and employees from and against all claims, damages, penalties, fines, injuries, losses, demands, lawsuits,
causes of action, and expenses (including attorneys’ fees) of any kind or nature whatsoever arising out of, in connection with,
or resulting from (a) the making, using, importing, licensing, leasing, offering for sale, or selling of any products by Licensee,
or any sublicensee of Licensee, (b) a breach of any provision of this Agreement by Licensee, (c) the infringement, alleged infringement,
or violation by products produced by Licensee or the end users of the Brainlab software created pursuant
to this Agreement , based upon the Licensed Patents or Intellectual Property of any patent, copyright, trademark, service
mark, trade secret, or other intellectual property right owned by a third party, provided, however, that such infringement is not
the result of the Licensed Patents or Intellectual Property or the combination of Licensee’s products with any product of
Licensor, including, without limitation, the SmartFrame products, provided, that Licensor agrees to promptly notify Licensee
upon learning of any such claim, demand or cause of action, and provide Licensor with such assistance as reasonably requested by
Licensor in defending against such claim, demand or cause of action; provided, however, Licensee will not be released
from its indemnification obligations due to Licensor’s failure to give prompt notice of a claim, except to the extent that Licensee
is actually prejudiced by the failure to receive prompt notice of any such claim.

 

8.           
Non Assignment. This Agreement shall not be assigned or transferred in whole or in part by either party
without the prior written consent of the other; provided, that either party may assign this Agreement without notice or
prior written consent to an acquirer of all or substantially all of the assets or outstanding equity relating to such party’s
business or portion of its business to which this Agreement or the Licensed Products relate. Any purported assignment or transfer
in violation of this Section shall be void. This Agreement will bind and benefit the parties and their successors and assigns.
Notwithstanding the above, Licensee may assign this Agreement to an entity that is an Affiliate of Licensee as of the Effective
Date. The validity of any approved or allowable assignment of this Agreement or any of the rights or privileges under this Agreement
shall be subject to the assignee agreeing in advance in writing to be bound by the terms of this Agreement.

 

9.           
Infringement by Third Parties. In the case that either Licensor or Licensee becomes aware of any actual
or potential infringement by a third party of any of the Intellectual Property or the Licensed Patents, the party gaining such
knowledge shall promptly notify the other. Promptly following such notice, Licensor and Licensee shall confer and consider bringing
a joint action. In the event that Licensor and Licensee agree not to file a joint action, Licensor shall have the initial right
(but not the obligation) to bring suit and initiate proceedings relating to any infringement of the Licensed Patents and to settle
the same and Licensee agrees that Licensor may cause Licensee to join it as a party to any such suit at no expense to Licensee
if necessary for Licensor to have proper standing to bring such action. If Licensor declines to bring such claim, Licensee shall
then be afforded the right to bring suit and initiate

 

    	5

    	 

    

 

proceedings relating to any infringement of the Licensed Patents and to settle
the same and Licensor agrees that Licensee may cause Licensor to join it as a party to any such suit at no expense to Licensor
if necessary for Licensee to have proper standing to bring such action. All costs and expenses relating to any such suit or suits
or proceeding shall be paid for by the party bringing suit or initiating proceedings, and any and all recoveries, awards, or payments
from said suits or any settlements thereof shall be the property of such party; provided that in the case of a joint action,
the Licensor and Licensee shall agree, prior to commencing such action, on a proper allocation of any recovery or award. Each of
Licensor and Licensee shall reasonably cooperate with and assist the other in all such suits as Licensee deems reasonably appropriate
or necessary and all costs and expenses thereof shall be borne by the party bringing suit or imitating proceedings. If either party
becomes aware of any infringement of the Patents or misappropriation of the Technology or Improvements by any third-party, such
party shall promptly notify the other party of such and provide the other party with any and all evidence thereof in its possession
or control.

 

		10.	Prosecution.

 

10.1         
By Licensor. Licensor shall prosecute and/or maintain all of the Licensed Patents and any other intellectual
property rights relating thereto. Licensor shall promptly provide Licensee with copies of all non-privileged correspondence from
and with the U.S. Patent and Trademark Office and all worldwide patent offices relating to the Licensed Patents. Licensee shall
have the right to provide suggestions to Licensor with respect to prosecution of the Licensed Patents and all suggestions of Licensee
shall be reasonably considered in good faith by Licensor.

 

10.2         
Failure to Prosecute. Should Licensor fail to prosecute or maintain any of the Licensed Patents or pay for
the prosecution of any of the Licensed Patents, Licensee shall, in addition to any other remedies available to Licensee, have the
right to prosecute and/or maintain such Licensed Patents and Licensor shall reimburse Licensee promptly upon demand for all costs
incurred by Licensee in connection therewith. The foregoing obligation shall not apply to certain patent applications or patents
for countries outside the United States for which Licensor decides not to further prosecute or maintain the patent application
or patent, provided, that Licensee shall have the right to acquire Licensor’s rights in the specific foreign country for
each such patent application or patent for which Licensor makes such a determination and Licensee shall be responsible for any
and all costs or fees incurred in connection with such patent application or patent in that specific country.

 

		11.	Information and Confidentiality.

 

11.1         
Confidentiality. Licensor and Licensee acknowledge that the Licensed Patents and Intellectual Property and
other information provided by the parties to one another pursuant to this Agreement relates or will relate to information that
is not or will not be publicly available (“Confidential Information”). The Confidential Information provided
hereunder is valuable, proprietary, and unique, and each party agrees to maintain the confidentiality of the Confidential Information
and to be bound by and observe the proprietary nature thereof as provided herein. Each party agrees to take diligent action to
fulfill its obligations hereunder by instruction or agreement with its directors, officers, employees, agents or Affiliates (whose
confidentiality obligations shall survive termination of employment or agency) who are permitted access to the Confidential Information.
Access shall only be given on a need-to-know basis, except as otherwise set forth herein or as may be permitted in writing by the
disclosing party. Except as set forth herein, neither party shall use, nor provide nor otherwise make available the Confidential
Information or any part or copies thereof to any third party, other than as agreed to in writing in advance by the disclosing party.
Prior to any such disclosure, each party to whom Confidential Information is to be disclosed shall agree to terms and conditions
concerning exchange of information and confidentially as laid down in this Section 12.1. The terms and conditions of this Agreement
are also confidential to the

 

    	6

    	 

    

 

parties.
Neither party shall disclose any such terms and conditions during the term of this Agreement and thereafter without prior written
approval by the other party, except as required by law. Notwithstanding anything the contrary contained herein, Licensee may communicate
all information, including Confidential Information, as it reasonably deems appropriate to actual or potential end users and customers
for the purpose of selling, maintaining and servicing products produced using any Intellectual Property or Licensed Patents, provided,
however, that Licensee shall use reasonable efforts to cause such potential end users and customers to retain the confidentiality
of Confidential Information.

 

11.2         
Injunctive Relief. Each party acknowledges and agrees that the unauthorized use or disclosure of the Confidential
Information or any part thereof is likely to cause irreparable injury to the other party, who shall therefore be entitled to seek
injunctive relief to enforce the rights and obligations under this Agreement, in addition to any other remedies available at law,
in equity, or under this Agreement, and without the need to post a bond even if ordinarily required.

 

11.3         
Confidentiality Exceptions. Notwithstanding the provisions of this Section 12, the confidentiality obligations
hereunder shall not apply to (i) information that is known to the public or is generally known within the industry or business,
(ii) information that was legally acquired by Licensor or Licensee, as the case may be, from a third-party in good faith, provided
that such disclosure by the third-party was not in breach of any agreement between such third-party and Licensor or Licensee, as
the case may be, (iii) information that was required to be disclosed pursuant to law or order of a court having jurisdiction (provided
that the party required so to disclose such Confidential Information shall offer the party owning such Confidential Information
the opportunity to obtain an appropriate protective order or administrative relief against disclosure of such Confidential Information)
but only to the extent of any such required disclosure, and (iv) information that Licensee needs to disclose to existing and potential
investors, subject to any such existing and potential investors agreeing to be bound by the confidentiality obligations hereunder.

 

12.         
Survival. The terms of Articles 3, 4, 6, 7, 9, 11, 12 and13 shall survive the termination or expiration
of this Agreement.

 

13.         
General Provisions.

 

13.1         
Choice of Law. This Agreement will be governed by, and construed and interpreted according to, the substantive
laws of the State of New York, without regard to its choice of law provisions.

 

13.2         
Dispute Resolution. Except as otherwise expressly provided in this Agreement, all claims, controversies or
disputes arising out of or related to this Agreement, or any breach thereof, shall be resolved by binding arbitration in New York,
New York as provided herein and otherwise in accordance with the Commercial Arbitration rules of the American Arbitration Association.
Where the amount in controversy is less than $1,000,000.00, the dispute shall be submitted to a single arbitrator. Otherwise the
dispute shall be submitted to a panel of three arbitrators. The arbitrator(s) shall strictly enforce all provisions of this Agreement
except to the extent applicable law requires otherwise. The arbitrator(s) shall have no authority to grant either party punitive,
exemplary, consequential or other special damages of any kind. Judgment upon the award of the arbitrator(s) may be entered in any
court of competent jurisdiction. The arbitration panel shall award to the prevailing party all of such party’s costs related
to the controversy (including without limitation attorneys’ fees and out-of-pocket expenses). Where each party prevails in
part, the tribunal shall award to each party that part of its costs which the tribunal deems allocable to those issues as to which
such party prevailed

 

    	7

    	 

    

 

13.3         
Rights in Bankruptcy. Notwithstanding any other provision of this Agreement to the contrary, Licensor hereby
recognizes and agrees that in the event of the commencement of any proceedings in bankruptcy by or against Licensor or providing
for the liquidation or reorganization of Licensor, or alleging that Licensor is insolvent or unable to pay its debts as they mature,
or providing for an assignment for the benefit of creditors , or for the readjustment or arrangement of any of Licensor’s debts
pursuant to the United States Bankruptcy Code (11 U.S.C. §101 et. seq. (the “Bankruptcy Code”)) or under
any other insolvency law, if Licensor rejects this Agreement pursuant to Section 365(n) of the Bankruptcy Code (a “Bankruptcy
Rejection”), (i) any and all of the licensee and sub-licensee rights of Licensee arising under or otherwise set forth
in this Agreement, including without limitation the Intellectual Property and the Licensed Patents shall be deemed fully retained
by and vested in Licensee as protected intellectual property rights under Section 365(n)(1)(b) of the Bankruptcy Code and further
shall be deemed to exist as such rights existed immediately before the commencement of the bankruptcy case in which Licensor is
the debtor; (ii) Licensee shall have all of the rights afforded to non-debtor licensees and sub-licensees under Section 365(n)
of the Bankruptcy Code; and (iii) to the extent any rights of Licensee under this Agreement which arise after the termination or
expiration of this Agreement are determined by a bankruptcy court not to be “intellectual property rights” for
purposes of Section 365(n), all of such rights, including the right to use any trademarks, shall remain vested in and fully retained
by Licensee (to the extent of any applicable state law) after any Bankruptcy Rejection as though this Agreement were terminated
or expired. Unless and until this Agreement is rejected pursuant to Section 365(n) of the Bankruptcy Code, Licensor further hereby
recognizes and agrees that it must, upon the Licensee’s written request, perform under this Agreement and is prohibited from interfering
with the Licensee’s rights pertaining to the Intellectual Property and the Licensed Patents, including all intellectual property
rights related thereto. Licensee shall under no circumstances be required to terminate this Agreement after a Bankruptcy Rejection
in order to enjoy or acquire any of its rights under this Agreement.

 

13.4         
Entire Agreement. This Agreement is the final and entire agreement between the parties relating to the subject
matter and supersedes any and all prior or contemporaneous discussions, statements, representations, warranties, correspondence,
conditions, negotiations, understandings, promises and agreements, oral and written, with respect to such subject matter.

 

13.5         
No Reliance. The parties each acknowledge that, in entering into this Agreement, they have not relied upon
any statements, representations, warranties, correspondence, negotiations, conditions, understandings, promises and agreements,
oral or written, not specifically set forth in this Agreement. All of the parties represent that they are represented by legal
counsel and have been fully advised as to the meaning and consequence of all of the terms and provisions of this Agreement.

 

13.6         
Waiver; Modifications. No provision of this Agreement shall be waived unless set forth in writing and signed
by the party effecting such waiver. No waiver of the breach of any of the terms or provisions of this Agreement shall be a waiver
of any preceding or succeeding breach of this Agreement or any other provisions thereof. No waiver of any default, express or implied,
made by any party hereto shall be binding upon the party making such waiver in the event of a subsequent default. This Agreement
may only be modified or amended by a written agreement executed by each of the parties.

 

13.7         
Notices. Any notices permitted or required under the provisions of this Agreement shall be in writing and
shall be personally delivered, mailed by certified mail, postage prepaid or by facsimile transmission (with proof of transmission)
or shall be sent by overnight courier service to the address of the relevant party as first set forth above. Licensor or Licensee
may direct notices to be sent to such other address or Person as any party may have specified in a notice duly given to the other
party as provided herein. Such notice, request, demand, waiver, consent, approval or other communication will be deemed to have
been given as of the date so delivered.

 

    	8

    	 

    

 

13.8         
Severability. In the event that any one or more of the provisions contained in this Agreement shall, for any
reason, be held to be invalid, void, illegal, or unenforceable in any respect, such invalidity, voidness, illegality or unenforceability
shall not affect any other provision of this Agreement, and the remaining portions shall remain in full force.

 

13.9         
Cooperation. Each of the parties hereto shall execute and deliver any and all additional papers, documents,
and other assurances, and shall do any and all acts and things reasonably necessary in connection with the performance of their
obligations hereunder and to carry out the intent of the parties hereto.

 

13.10     
   Titles. Some sections of this Agreement have titles and some do not. The fact that some sections hereof do
not have titles shall have no significance. The titles are included for ease of reference only, and shall not be used to construe
the meaning of this Agreement.

 

13.11       
Authority. All parties and authorized representatives signing this Agreement represent and warrant that they
have authority to execute and enter into this Agreement.

 

13.12        
Counterparts. This Agreement may be executed in multiple counterparts, all of which shall constitute a single
agreement binding on the parties. Facsimile signatures shall be binding for all purposes.

 

[Signature Page Follows]

 

    	9

    	 

    

 

[Signature
Page to Patent and Technology License Agreement]

 

IN WITNESS WHEREOF,
the parties have executed this Patent and Technology License Agreement through their duly authorized representatives as of the
Effective Date.

	 	 	 	 
	 	MRI INTERVENTIONS, INC.	 
	 	 	 	 
	 	By:	 	 
	 	Name:	Francis P. Grillo	 
	 	Its:	Chief Executive Officer	 
	 	 	 	 
	 	BRAINLAB AG	 
	 	 	 	 
	 	By:	 	 
	 	Name:	 	 
	 	Its:	 	 

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]